{"id":750843,"date":"2023-04-25T10:07:27","date_gmt":"2023-04-25T14:07:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"},"modified":"2023-04-25T10:07:27","modified_gmt":"2023-04-25T14:07:27","slug":"allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","title":{"rendered":"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Conference Call and Webcast Scheduled for 2:00 PM PT\/5:00 PM ET<\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif., April  25, 2023  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time\/5:00 PM Eastern Time.<\/p>\n<p>\n        <strong>Listen-Only Webcast<\/strong><br \/>\n        <br \/>The listen-only webcast will be made available on the Company&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zfoOcvUbkZdQTEUK-Vyp-c5Oa5XuoyM-HOJ1xv13goCiGXUzo0dOE-qfQozsyNS0lMg0ut4I66-N1e-SXDk3Zg==\" rel=\"nofollow noopener\" target=\"_blank\">www.allogene.com<\/a> under the Investors tab in the News and Events section. A replay will be available on the Company&#8217;s website for approximately 30 days.<\/p>\n<p>\n        <strong>Conference Call Registration <\/strong><br \/>\n        <br \/>If you would like the option to ask a question on the conference call, please use <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=opAUyzg1ZA--LdPlqUqFqfQhBKpeDhIoFsNoewLMltBcw5H2wiUGL-LA6RPpoFUsd33TCsvuio-R5d6F8eX42n0ibL5H7IWiAiPv_beM44B93iqQq6dK3JzdoKg5NMXkQDD-SNfqtUhsDDnLTYrMjA==\" rel=\"nofollow noopener\" target=\"_blank\">this link<\/a> to register. Upon registering for the conference call, you will receive a personal PIN to access the call.<\/p>\n<p>\n        <strong>About Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T\u2122) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene\u2019s expectations and actual results as discussed in greater detail in Allogene\u2019s filings with the Securities and Exchange Commission (SEC), including without limitation under the \u201cRisk Factors\u201d heading of its Form 10-K for the year ended\u00a0December 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>AlloCAR T\u2122 is a trademark of Allogene Therapeutics, Inc.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>Chief Communications Officer<br \/>(714) 552-0326<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RHTHCoFSdKnsK7Bucm_Qo8-x_6hBwdX_xhlIzy0w8RZh6oVUR4l6d4HG6fj6w8rWugd9axP9OtVIma-5d_cDOjNU50B82Aas92rEfFOSPg-m4_8V1P0kPJ9jtEnE64Ac\" rel=\"nofollow noopener\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmRiNDcxODYtMGE2Zi00OTJiLWJkNDktNWVhZWVhNWJiOTliLTExMzU4MTg=\/tiny\/Allogene-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Webcast Scheduled for 2:00 PM PT\/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time\/5:00 PM Eastern Time. Listen-Only Webcast The listen-only webcast will be made available on the Company&#8217;s website at\u00a0www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company&#8217;s website for approximately &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750843","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast Scheduled for 2:00 PM PT\/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time\/5:00 PM Eastern Time. Listen-Only Webcast The listen-only webcast will be made available on the Company&#8217;s website at\u00a0www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company&#8217;s website for approximately &hellip; Continue reading &quot;Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T14:07:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023\",\"datePublished\":\"2023-04-25T14:07:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\"},\"wordCount\":449,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\",\"name\":\"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=\",\"datePublished\":\"2023-04-25T14:07:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk","og_description":"Conference Call and Webcast Scheduled for 2:00 PM PT\/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time\/5:00 PM Eastern Time. Listen-Only Webcast The listen-only webcast will be made available on the Company&#8217;s website at\u00a0www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company&#8217;s website for approximately &hellip; Continue reading \"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T14:07:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023","datePublished":"2023-04-25T14:07:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"},"wordCount":449,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","name":"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=","datePublished":"2023-04-25T14:07:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU2NyM1NTUzNDE4IzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750843"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750843\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}